- Home
- SKYE vs SCPH Comparison
SKYE vs SCPH Comparison
Compare SKYE & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- SCPH
- Stock Information
- Founded
- SKYE 2012
- SCPH 2013
- Country
- SKYE United States
- SCPH United States
- Employees
- SKYE N/A
- SCPH N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- SKYE Health Care
- SCPH Health Care
- Exchange
- SKYE Nasdaq
- SCPH Nasdaq
- Market Cap
- SKYE 108.5M
- SCPH 299.0M
- IPO Year
- SKYE N/A
- SCPH 2017
- Fundamental
- Price
- SKYE $3.86
- SCPH $5.62
- Analyst Decision
- SKYE Buy
- SCPH Buy
- Analyst Count
- SKYE 7
- SCPH 3
- Target Price
- SKYE $15.50
- SCPH $12.00
- AVG Volume (30 Days)
- SKYE 316.3K
- SCPH 2.4M
- Earning Date
- SKYE 11-06-2025
- SCPH 11-12-2025
- Dividend Yield
- SKYE N/A
- SCPH N/A
- EPS Growth
- SKYE N/A
- SCPH N/A
- EPS
- SKYE N/A
- SCPH N/A
- Revenue
- SKYE N/A
- SCPH $49,969,000.00
- Revenue This Year
- SKYE N/A
- SCPH $108.95
- Revenue Next Year
- SKYE N/A
- SCPH $78.30
- P/E Ratio
- SKYE N/A
- SCPH N/A
- Revenue Growth
- SKYE N/A
- SCPH 107.79
- 52 Week Low
- SKYE $1.14
- SCPH $1.94
- 52 Week High
- SKYE $6.13
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- SKYE 52.64
- SCPH 52.96
- Support Level
- SKYE $3.96
- SCPH N/A
- Resistance Level
- SKYE $4.55
- SCPH $5.62
- Average True Range (ATR)
- SKYE 0.31
- SCPH 0.04
- MACD
- SKYE 0.04
- SCPH -0.21
- Stochastic Oscillator
- SKYE 45.67
- SCPH 99.56
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.